21 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Metanalisi

Efficacy and safety of traditional Chinese medicine kidney-tonifying and blood-activating therapy in the treatment of vascular dementia: a systematic review and meta-analysis.

Mengdie Zhou, Mengqi Che, Chao Zhang, Xiaoyu Yang, Xile Liu, Zhihao Liu, Ju Huang, Hua He

Frontiers in neurology · 2026

Abstract originale

OBJECTIVE: This meta-analysis evaluated the efficacy and safety of Kidney-tonifying and Blood-activating Therapy (KTBAT) for vascular dementia (VaD). METHODS: Eight electronic databases were systematically searched from inception to January 12, 2026, for randomized controlled trials (RCTs). Primary endpoints included clinical effectiveness and cognitive scores (MMSE, HDS, CDR). Secondary outcomes focused on neurotrophic factors (BDNF, NGF, GDNF). Study quality was assessed via RoB 1, with data synthesis performed using RevMan 5.4. RESULTS: Thirty-eight RCTs involving 3,357 participants were identified. KTBAT, whether administered as monotherapy or combined with Western medicine (WMT), significantly increased the clinical effectiveness rate compared to WMT (RR = 1.25, 95% CI: [1.20, 1.31]). Regarding cognition, KTBAT significantly improved MMSE (MD = 3.71, 95% CI: [2.96, 4.47]) and HDS scores (MD = 4.07, 95% CI: [2.63, 5.52]). CDR scores were also lower after intervention (SMD = -0.87, 95% CI: [-1.26, -0.47]). Additionally, KTBAT was associated with higher serum levels of BDNF (SMD = 1.02, 95% CI: [0.13, 1.90]) and NGF (SMD = 0.69, 95% CI: [0.27, 1.12]). GDNF was assessed in only one trial, and its level was also higher in the intervention group. Adverse events (AEs) rates did not differ significantly between KTBAT and WMT (RR = 0.71, 95% CI: [0.32, 1.57], p = 0.40), with no serious AEs or deaths reported. CONCLUSION: KTBAT appears to be a potentially effective intervention for improving clinical effectiveness and cognitive function in VaD; however, its safety profile remains uncertain. While these findings support KTBAT as a promising candidate for VaD management, further high-quality, multicenter trials are warranted to strengthen the evidence base. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/search, identifier CRD420251272344.

Parole chiave

HumansDementia, VascularDrugs, Chinese HerbalMedicine, Chinese TraditionalRandomized Controlled Trials as Topickidney-tonifying and blood-activating therapymeta-analysissystematic reviewtraditional Chinese medicinevascular dementia
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Efficacy and safety of traditional Chinese medicine kidney-tonifying and blood-activating therapy in the treatment of vascular dementia: a systematic review and meta-analysis

Objective

This meta-analysis evaluated the efficacy and safety of Kidney-tonifying and Blood-activating Therapy (KTBAT) for vascular dementia (VaD).

Methods

Eight electronic databases were systematically searched from inception to January 12, 2026, for randomized controlled trials (RCTs). Primary endpoints included clinical effectiveness and cognitive scores (MMSE, HDS, CDR). Secondary outcomes focused on neurotrophic factors (BDNF, NGF, GDNF). Study quality was assessed via RoB 1, with data synthesis performed using RevMan 5.4.

Results

Thirty-eight RCTs involving 3,357 participants were identified. KTBAT, whether administered as monotherapy or combined with Western medicine (WMT), significantly increased the clinical effectiveness rate compared to WMT (RR = 1.25, 95% CI: [1.20, 1.31]). Regarding cognition, KTBAT significantly improved MMSE (MD = 3.71, 95% CI: [2.96, 4.47]) and HDS scores (MD = 4.07, 95% CI: [2.63, 5.52]). CDR scores were also lower after intervention (SMD = −0.87, 95% CI: [−1.26, −0.47]). Additionally, KTBAT was associated with higher serum levels of BDNF (SMD = 1.02, 95% CI: [0.13, 1.90]) and NGF (SMD = 0.69, 95% CI: [0.27, 1.12]). GDNF was assessed in only one trial, and its level was also higher in the intervention group. Adverse events (AEs) rates did not differ significantly between KTBAT and WMT (RR = 0.71, 95% CI: [0.32, 1.57], p = 0.40), with no serious AEs or deaths reported.

Conclusion

KTBAT appears to be a potentially effective intervention for improving clinical effectiveness and cognitive function in VaD; however, its safety profile remains uncertain. While these findings support KTBAT as a promising candidate for VaD management, further high-quality, multicenter trials are warranted to strengthen the evidence base.

Systematic review registration

https://www.crd.york.ac.uk/prospero/search, identifier CRD420251272344.

1Introduction

As the global population continues to age, dementia has become a major public health concern worldwide. Vascular dementia (VaD), which is caused by cerebrovascular disease, is the second most common type of dementia after Alzheimer’s disease (AD) (1). Previous studies have shown that pure VaD represents about 15% of all dementia cases, affecting an estimated 8.5 million people globally (2). In China, the prevalence of dementia in adults aged 60 years and older is approximately 6.0%, among whom VaD accounts for 1.6% (3). Clinically, VaD is characterized by marked deficits in several cognitive domains, including memory, attention, executive function, and language, often together with focal neurological signs (4). Despite its substantial disease burden, currently, no therapeutic intervention has been definitively established to halt or reverse disease progression (5, 6). Clinical management primarily focuses on slowing cognitive decline, with cholinesterase inhibitors and memantine being the most commonly employed pharmacological agents (7, 8). In addition, international consensus recommends comprehensive control of vascular risk factors, including hypertension and diabetes mellitus, as an important approach to slowing disease progression (9). However, existing pharmacotherapies provide symptomatic effects with limited ability to modify the underlying disease progression. Moreover, their long-term use is often restricted by adverse events (AEs), such as gastrointestinal disturbances and dizziness (10, 11). Due to the limited availability of highly effective clinical options, there is a clear need to investigate complementary and alternative therapeutic strategies, among which traditional Chinese medicine (TCM) represents a promising avenue.

Within TCM theory, VaD is referred to as “dementia (Chi Dai)” or “forgetfulness (Jian Wang)” (12). In terms of etiology and pathogenesis, VaD is linked to “kidney deficiency” (Shen Xu) and “blood stasis” (Xue Yu). Notably, pathological conditions such as metabolic syndrome and coagulation abnormalities (13) align with TCM concepts such as “phlegm-dampness (Tan Shi)” and blood stasis. Both phlegm-dampness and blood stasis have been recognized as established risk factors for cerebrovascular disease and cognitive impairment (14, 15). Blood stasis, meanwhile, describes a state of impaired microcirculation and reduced tissue oxygenation. Therefore, the treatment protocol for VaD in TCM includes the Kidney-tonifying and Blood-activating Therapy (KTBAT) (16). In this review, KTBAT was operationally defined as Chinese herbal interventions—including decoctions, granules, capsules, tablets, and patent medicines—whose primary therapeutic principle is kidney-tonifying and blood-activating, and which contain both kidney-tonifying and blood-activating components for the treatment of VaD. Therefore, pooling these interventions reflects the overall effect of the KTBAT principle, rather than the effect of one specific formula. This therapeutic approach incorporates Chinese herbal medicines (CHMs) that simultaneously tonify the kidneys and activate blood circulation. Classic and modern formulations, such as Buyang Huanwu Tang, Dihuang Yinzi, and Bushen Huoxue Tang, have been widely adopted (17–19). Contemporary pharmacological research indicates that KTBAT exerts multiple effects, including improving cerebral blood flow, having anti-inflammatory properties, antioxidant activity, inhibiting neuronal apoptosis, activating mitophagy, and providing neuroprotection (20–23). KTBAT may also enhance neurotransmitters and offer neuroprotective actions (24, 25). An increasing number of clinical trials have evaluated different KTBAT formulations for VaD (26). However, the methodological quality of these studies varies substantially, and their findings are not fully consistent. Specifically, the effectiveness of TCM for patients with severe dementia remains uncertain, and real-world data are limited.

Given this gap in the literature, TCM has attracted growing attention for its potential use in the management of VaD, and an increasing number of clinical studies have been conducted in this area. Nevertheless, a systematic synthesis and quantitative assessment of the available evidence are still lacking. Therefore, we performed this systematic review and meta-analysis to integrate the existing clinical evidence and evaluate the efficacy and safety of KTBAT for VaD. This study systematically evaluated clinical outcomes and safety of KTBAT in VaD by integrating previous RCTs. This review was conducted in accordance with the PRISMA 2020 guidelines.

2Materials and methods

2.1Protocol registration

This systematic review and meta-analysis was planned, undertaken, and reported in line with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The study protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO registration ID: CRD420251272344).

2.2Search strategy

The literature search covered the period from database inception through January 12, 2026. The databases searched were PubMed, Web of Science Core Collection (Web of Science), the Cochrane Central Register of Controlled Trials (CENTRAL), Excerpta Medica Database (Embase), Chinese Biomedical Literature Service System (Sino-Med), China National Knowledge Infrastructure (CNKI), VIP Chinese Journal Database (VIP), and Wanfang Data Knowledge Service Platform (Wanfang).

A combination of Medical Subject Headings (MeSH) and free-text keywords was used to identify records related to the condition, intervention, and study design. Search terms included, but were not limited to, “Dementia, Vascular, Vascular Dementia, Arteriosclerotic Dementia, kidney-tonifying and blood-activating, Bushen Huoxue, and Bushen Huoxue traditional Chinese medicine”. In addition, the reference lists of relevant reviews and eligible studies were manually screened to identify potentially missed articles. No restrictions were applied with regard to publication language or country of origin. The detailed search strategy is presented in Supplementary note 1.

2.3Eligibility criteria

Studies were screened and selected according to the PICOS framework.

Participants (P): Adult patients (aged ≥ 40 years) clinically diagnosed with VaD, regardless of gender, ethnicity, or nationality.

Interventions (I): TCM formulas (including decoctions, granules, or patent medicines) with kidney-tonifying and blood-activating effects, administered either as monotherapy or in combination with Western medicine treatment (WMT).

Comparison (C): Placebo control, WMT (including but not limited to nimodipine, donepezil, huperzine A, etc.), or no treatment (blank control).

Outcomes (O):

Primary outcome: The clinical effectiveness rate at the end of treatment is determined based on criteria such as MMSE score changes or global symptom assessment.

Secondary outcomes: Mini-Mental State Examination (MMSE); Hasegawa Dementia Scale (HDS); Clinical Dementia Rating Scale (CDR); brain-derived neurotrophic factor (BDNF); nerve growth factor (NGF); glial cell line-derived neurotrophic factor (GDNF); AEs.

Study design (S): Randomized controlled trials (RCTs).

2.4Exclusion criteria

Studies were excluded if they met any of the following criteria: (1) duplicate reports or overlapping datasets; (2) review articles, including systematic reviews and meta-analyses, as well as basic research or animal studies; (3) studies where the experimental or control group received additional interventions (e.g., acupuncture, rehabilitation therapy, physical therapy) beyond the predefined treatment protocols; (4) studies with incomplete data or unreported key outcome indicators; (5) the full text could not be retrieved or no extractable data were reported; (6) uncontrolled studies lacking a parallel control group.

2.5Selection process

Two reviewers (Zhou and Che) independently performed study selection in two steps. Titles and abstracts were first screened, followed by full-text assessment against the eligibility criteria. Any disagreement was resolved by discussion, and a third reviewer was consulted when consensus could not be reached. Duplicate records were identified and removed using EndNote 2025 (Clarivate Analytics, USA), with both automated and manual deduplication procedures applied. The entire selection workflow, from identification to final inclusion, is depicted in a PRISMA 2020 flow diagram.

2.6Data collection process

Data extraction was carried out independently by the same two reviewers using a pretested standardized form. The following information was collected from each eligible study: first author, publication year, country, sample size, participant characteristics, intervention and comparator details, treatment duration, outcome definitions, numerical results, and AEs. When relevant information was missing or unclear, attempts were made to contact the corresponding authors for clarification. All data were entered into Microsoft Excel for organization and analysis. The extracted information was then cross-checked, and any discrepancies were resolved through discussion or, if necessary, by consultation with a third reviewer.

2.7Study risk of bias assessment

The methodological quality of the included RCTs was independently evaluated by two reviewers (Zhou and Che) using the Cochrane Risk of Bias tool version 1 (RoB 1). The assessed domains included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Each domain was categorized as low, unclear, or high risk of bias, and an overall judgment was assigned to each study accordingly. Discrepancies were settled through discussion or, when needed, by adjudication from a third reviewer.

2.8Data synthesis and statistical analysis

Statistical analyses were performed using Review Manager software (RevMan version 5.4; The Nordic Cochrane Centre). Meta-analysis was conducted when at least two studies reported sufficiently comparable interventions, outcomes, and study designs. Statistical heterogeneity was examined using Cochran’s Q test and quantified with the I2 statistic.

For dichotomous outcomes, such as the clinical effectiveness rate, pooled effect sizes were expressed as risk ratios (RRs) with 95% confidence intervals (CIs). The clinical effectiveness rate was extracted as a dichotomous outcome (effective vs. ineffective) according to the definition provided in each original study. For continuous outcomes, mean differences (MDs) with 95% CIs were calculated when the same measurement scale was used across studies; otherwise, standardized mean differences (SMDs) with 95% CIs were applied.

A fixed-effect model was used when heterogeneity was low (I2 ≤ 50% and p ≥ 0.10 for the Q-test), indicating that the observed variation across studies was likely due to chance. When heterogeneity was moderate to substantial (I2 > 50% and/or p < 0.10), a random-effects model was adopted to account for expected clinical and methodological differences across studies.

When substantial heterogeneity was identified, potential sources were explored through subgroup analyses and sensitivity analyses. Differences in participant characteristics, intervention dosage forms and treatment duration were considered as possible contributors to heterogeneity. A two-sided p value < 0.05 was considered statistically significant for pooled effect estimates.

For crossover trials, only first-period data were extracted. When first-period data were available, they were treated as parallel-group data and included in the primary quantitative synthesis. When only combined-period data or per-period data with repeated measures were reported, the trial was not included in the primary quantitative synthesis and was summarised narratively. The same rule was applied to safety outcomes.

2.9Subgroup analyses

To further explore potential sources of heterogeneity and maintain consistency with the predefined analytical framework, subgroup analyses were planned according to the following factors: treatment duration, categorized based on the intervention courses reported in the included studies; dosage form, such as different pharmaceutical or preparation forms of the intervention. Subgroup findings were interpreted cautiously due to the observational nature of between-subgroup comparisons.

2.10Sensitivity analyses

Sensitivity analyses were undertaken to evaluate the stability of the pooled findings. Specifically, leave-one-out analyses were performed by sequentially excluding one study at a time and recalculating the combined effect size to determine whether individual studies influenced the overall estimates or heterogeneity. Additional sensitivity analyses were planned to examine the impact of study quality, sample size, and model choice.

2.11Assessment of reporting biases

When a meta-analysis included at least 10 studies, funnel plots were generated to evaluate possible small-study effects and publication bias. However, the limited power of these methods was taken into account when the number of studies was small. It should be noted that an asymmetrical funnel plot does not necessarily indicate the presence of publication bias.

3Results

3.1Study selection

A total of 2,827 records were retrieved from eight electronic databases. After 1,173 duplicate entries were removed, 1,654 unique records remained for subsequent screening. Following evaluation of the titles and abstracts, 1,308 records were excluded because they did not satisfy the predefined eligibility criteria. The full texts of the remaining 346 articles were then obtained and assessed for eligibility; among them, three studies were excluded because the full texts were unavailable. Ultimately, 343 publications were independently evaluated by two researchers using RoB 1, resulting in the inclusion of 38 RCTs (27–64). The study selection process is presented in Figure 1.

3.2Study characteristics

A total of 38 articles (27–64) published between 2003 and 2025 were included in this review. All of the studies were conducted in China and reported in Chinese. The overall sample comprised 3,357 participants, with 1,692 assigned to the intervention group and 1,665 to the control group. The treatment period varied from 1 to 6 months. In all included trials, based on conventional Western medicine treatments (CWMT), such as antihypertensive and hypoglycemic therapies, the intervention group received TCM prescriptions or patent medicines focused on KTBAT, which were available in various formulations including capsules, granules, and tablets. Meanwhile, the control group received Western medicine treatment (WMT) or placebos, including donepezil, memantine, oxiracetam, and butylphthalide soft capsules. A clinical effectiveness rate was reported as an outcome measure in all included RCTs.

The included studies covered three comparison patterns. In 22 RCTs, KTBAT was combined with WMT, involving 962 patients in the intervention groups and 943 patients in the control groups. In 13 RCTs, KTBAT was used as monotherapy and compared with WMT, including 667 patients in the intervention groups and 659 patients in the control groups. In the remaining 3 RCTs, KTBAT was compared with placebo. These three crossover trials included 126 participants (63 in each group). Three placebo-controlled trials were crossover trials with non-poolable data. Additionally, nine studies documented the incidence of AEs; however, three crossover trials were not pooled for AEs, leaving six trials in the quantitative AE synthesis. The detailed characteristics of the included RCTs are summarized in Table 1.

Table 1Features of the included studies.

Author Country Study period Patients (N) Age Females Treatments Hospital stay Outcomes

T C T C T C T C

Dou and Gao (27) China 2018–2021 47 47 NR NR 22 23 Naoxintong Capsule + Piracetam Tablets + CWMT Piracetam Tablets + CWMT 3 months ①②

Guo et al. (28) China 2013–2016 60 60 65.12 ± 5.36 64.83 ± 4.97 34 32 Kidney-invigorating Blood-activating Tablets Citicoline Tablets 8 weeks ①②③⑧

Han et al. (29) China 2018–2020 54 54 64.82 ± 4.00 64.25 ± 4.13 24 26 Naoxintong Capsule + Nimodipine Tablets + CWMT Nimodipine Tablets + CWMT 8 weeks ①②④⑥⑦

Hu et al. (30) China 2019–2022 50 50 67.83 ± 8.03 66.99 ± 9.77 25 24 Dihuang Yinzi Piracetam Tablets 12 weeks ①②

Hu and Yu (31) China 2008–2010 37 30 65.06 ± 7.75 67.12 ± 8.51 15 13 Piracetam+FuYuanDecoction Piracetam 2 months ①

Huang (32) China 2017–2019 53 50 61.50 ± 5.80 60.90 ± 7.10 24 20 Naoxintong Capsule + Nimodipine Tablets + CWMT Nimodipine Tablets + CWMT 6 months ①②③⑥⑧

Jiang and Xu (33) China 2011–2012 34 32 60.38 ± 2.54 60.56 ± 2.34 13 13 Aricept + Naoxintong Capsule + CWMT Aricept + CWMT 8 weeks ①②⑤

Jiang (34) China 2003–2006 30 30 65.50 ± 4.20 64.70 ± 5.00 12 13 Naoxintong Capsule + Duxil Duxil 2 months ①③

Jin et al. (35) China NR 36 36 73.94 ± 7.77 73.94 ± 7.77 18 18 Jiannao Yizhi Capsule Placebo Capsules 12 weeks ①②③⑧

Li (36) China 2017–2020 48 48 70.05 ± 3.87 68.82 ± 3.61 15 17 CWMT + Bushen Huoxue Yizhi Decoction Butylphthalide + CWMT 6 months ①②④

Li et al. (37) China 2012–2014 57 53 70.40 ± 5.70 69.50 ± 6.20 22 21 Donepezi + CWMT + Dihuang Yinzi Capsule Donepezi + CWMT 180 days ①②

Li (38) China 2014–2016 119 119 67.32 ± 7.43 66.85 ± 3.96 51 47 Naoxintong Capsule + CWMT Nimodipine Tablets + CWMT 6 months ①②③⑤⑧

Liu (39) China 2016–2018 88 88 73.90 ± 6.50 74.40 ± 6.60 41 39 Bushen Yizhi Decoction Butylphthalide Capsules 6 months ①②④

Lu et al. (40) China 2018–2020 48 48 65.71 ± 11.46 64.32 ± 10.76 23 22 Naoxintong Capsule + Donepezil Hydrochloride + CWMT Donepezil Hydrochloride + CWMT 2 months ①②⑥

Ma et al. (41) China 2015–2017 46 46 66.73 ± 5.10 66.58 ± 4.95 20 21 Bushen Huoxue Decoction + CWMT + Rehabilitation Nursing Intervention Donepezil + CWMT + Rehabilitation Nursing Intervention 90 days ①②③

Man et al. (42) China 2016–2018 47 47 60.48 ± 6.73 60.61 ± 6.85 NR NR Naoxintong Capsule + Memantine Hydrochloride Tablet Memantine Hydrochloride Tablet 2 months ①②

Peng and Deng (43) China NR 28 28 68.50 ± 7.85 64.30 ± 8.14 10 9 Huayu Yizhi mixture Hydergine 2 months ①②③

Shao (44) China NR 31 24 NR NR 10 9 Xingnao Fusu Decoction Hydergine 2 months ①②

Sheng et al. (45) China 2005–2008 45 45 66.25 ± 7.16 68.13 ± 8.16 17 19 Naoxintong Capsule Duxil 12 weeks ①②③

Tang et al. (46) China 2001–2004 40 40 65.30 ± 7.80 64.60 ± 5.60 17 15 Bushen Huoxue Decoction Nimodipine + Duxil 3 months ①②⑤

Tao et al. (47) China 2013–2015 46 46 70.20 ± 5.30 69.80 ± 5.70 17 19 Yizhi Decoction + Oxiracetam Injection Oxiracetam Injection 3 weeks ①②⑤

Wnag et al. (48) China NR 9 9 73.94 ± 7.77 73.94 ± 7.77 2 2 Shenlong Decoction Placebo 3 months ①②③⑤⑧

Wang et al. (49) China 2000–2004 18 18 73.14 ± 6.71 73.14 ± 6.71 6 6 Shen Long Decoction Placebo 3 months ①⑧

Wang et al. (50) China 2019–2022 31 31 60.94 ± 6.38 59.75 ± 5.72 12 13 Bushen Huazhuo Huoxue Decoction + Memantine Hydrochloride Memantine Hydrochloride 24 weeks ①②⑥⑧

Wang (51) China 2010–2013 30 30 NR NR NR NR Xinjia Dihuang Yinzi + Aspirin enteric-coated tablets + Piracetam Tablets Aspirin enteric-coated tablets +Piracetam Tablets 3 months ①②

Wan g et al. (52) China 2013–2015 38 38 71.20 ± 5.40 70.40 ± 6.20 16 13 Tongqiao Huoxue Decoction + Oxiracetam Capsules Oxiracetam Capsules 1 month ①②

Wu et al. (53) China 2023–2024 32 32 NR NR NR NR Dihuang Yinzi + Donepezil Hydrochloride Tablets + CWMT Donepezil Hydrochloride Tablets + CWMT 90 days ①②

Wu et al. (54) China 2017–2019 50 50 67.05 ± 5.92 66.73 ± 5.89 22 21 Kaixin powder and Tongqiao Huoxue tang Donepezil tablets + Nimodipine tablets 16 weeks ①②

Yang et al. (55) China 2022–2023 38 37 67.13 ± 8.17 67.11 ± 8.16 15 17 CWMT + Jiawei Dihuang Yinzi granules CWMT 3 months ①②

Yang et al. (56) China 2016–2017 42 40 66.30 ± 2.50 65.70 ± 2.60 22 19 Naoxintong Capsule + Nimodipine Tablets + CWMT Nimodipine Tablets + CWMT 3 months ①②

Yao et al. (57) China 2014–2016 51 51 64.01 ± 7.75 63.51 ± 7.89 21 22 Donepezi + CWMT + Gunao Yizhi Tang Donepezi + CWMT 3 months ①②

Yao and Yang (58) China 2017–2019 39 39 65.34 ± 3.56 66.18 ± 3.47 16 17 Naoxintong Capsule + Nimodipine Tablets + CWMT Nimodipine Tablets + CWMT 6 months ①③

Yu (59) China 2016–2017 44 44 68.50 ± 5.20 67.30 ± 5.40 18 17 Wenshen Huoxue Recipe + Oxiracetam Capsules + CWMT Oxiracetam Capsules + CWMT 3 months ①

Yuang and Zhang (60) China 2021–2024 50 50 69.02 ± 4.32 68.44 ± 4.16 25 24 CWMT + Bushen Huayu Fang Nimodipine + CWMT 2 months ①②⑤⑥⑧

Zhao (61) China 2021–2023 49 49 67.44 ± 6.78 67.52 ± 6.55 23 22 Tongqiao Huoxue Decoction + Butylphthalide Soft Capsules + CWMT Butylphthalide Soft Capsules + CWMT 30 days ①

Zheng et al. (62) China 2006–2009 27 26 67.8 ± 5.7(60) 67.8 ± 5.7(60) 24 (60) 24 (60) Naoxintong Capsule + CWMT Nimodipine Tablets + CWMT 3 months ①②

Zhong et al. (63) China 2017–2018 35 35 63.31 ± 7.83 64.14 ± 6.48 14 16 Bushen Huoxue Decoction + CWMT Donepezil + CWMT 60 days ①②⑧

Zhu (64) China 2012–2014 65 65 NR NR 29 31 Naoxintong Capsule + Nimodipine Tablets + CWMT Nimodipine Tablets + CWMT 6 months ①②

AEs: adverse events; BDNF: brain-derived neurotrophic factor; C: control group; CWMT: conventional Western medicine treatments; CDR: Clinical Dementia Rating Scale; GDNF: glial cell line-derived neurotrophic factor; HDS: Hasegawa Dementia Scale; MMSE: Mini-Mental State Examination; NGF: nerve growth factor; NR: not reported; T: treatment group.

Outcome measures: ① Clinical effectiveness rate; ② MMSE; ③ HDS; ④ CDR; ⑤ BDNF; ⑥ NGF; ⑦ GDNF; ⑧AEs.

Analysis of the CHMs dosage forms utilized in the treatment groups revealed that decoctions were the most prevalent (n = 20), followed by capsules (n = 15). Other dosage forms, including granules, tablets, and mixtures, were each employed in a single study. Among the 38 RCTs, 25 of the most frequently appearing herbal decoction ingredients included Chuanxiong Rhizoma, Rehmanniae Radix Praeparata, Polygonum multiflorum, and Corni Fructus, among others. Although all studies applied the Kidney-tonifying and Blood-activating principle, the specific herbal compositions and dosage regimens varied across trials. The specific compositions and formulations of the KTBAT prescriptions identified in the included literature are summarized in Supplementary Table 2.

3.3Risk of bias in studies

We evaluated the quality of the 38 selected studies using the Cochrane Collaboration Risk of Bias tool (Figure 2).

3.3.1Randomization process

Twenty-two studies used a random number table to generate the allocation sequence and reported comparable baseline characteristics between groups; these studies were therefore considered to have a low risk of bias. For the remaining studies, however, the available information was insufficient to determine whether the randomization process was adequately implemented, and their risk of bias could not be confidently judged.

3.3.2Allocation concealment

Regarding allocation concealment, none of the 38 included trials provided sufficient details on concealment methods (e.g., sealed opaque envelopes and central allocation). Although all trials were described as randomized, the absence of explicit concealment information precluded a judgment of low risk. Therefore, all 38 trials were judged as having an “unclear risk of bias” for allocation concealment, and no trial was assessed as low risk of bias.

3.3.3Blind methods

Three articles (35, 48, 49) were judged as having a low risk of bias because they clearly described the blinding process. By comparison, the remaining trials were assigned an unclear risk of bias owing to inadequate reporting of blinding for participants, personnel, and outcome assessors.

3.3.4Missing outcome data

For incomplete outcome data, one study (34) was rated as high risk because prespecified outcome measures were not fully reported. The other studies either had no missing data or addressed missing data appropriately, and were thus classified as “low risk of bias”.

3.3.5Selective reporting

In terms of selective reporting, one trial (34) was judged as high risk due to incomplete reporting of prespecified outcome measures. Two studies (45, 49) were regarded as having an unclear risk of bias due to insufficient reporting of outcome measures. The remaining trials showed no selective bias in results, thus assessed as “low risk of bias”.

3.3.6Other potential sources of bias

No other potential sources of bias were identified across the 38 included trials.

3.4Efficacy outcomes

3.4.1Clinical effectiveness rate

All 38 included studies (27–64), encompassing a total of 3,357 patients, reported clinical effectiveness rate. Although the criteria for clinical effectiveness differed slightly across studies, they generally required the disappearance or marked alleviation of the main clinical symptoms. It is important to note that this outcome reflects a composite, symptom-based measure of global improvement (Supplementary Table 3).

For 22 RCTs comparing KTBAT combined with WMT versus WMT, a fixed-effect model showed no significant heterogeneity (I2 = 0%, p = 0.68). The pooled results indicated that the combination therapy was associated with a higher clinical effectiveness rate than WMT alone (RR = 1.25, 95% CI: [1.20, 1.31], p < 0.00001). Similarly, fixed-effect model analyses were conducted for 13 studies utilizing KTBAT as monotherapy versus WMT. The pooled results indicated low heterogeneity (I2 = 27%, p = 0.17). The pooled analysis showed that KTBAT was associated with a higher clinical effectiveness rate than WMT (RR = 1.26, 95% CI: [1.19, 1.34], p < 0.00001). The three placebo-controlled crossover trials (35, 48, 49) were not included in the quantitative synthesis (Figure 3).

3.4.2MMSE

A total of 32 RCTs reported MMSE scores as a measure of cognitive improvement (27–30, 32, 33, 35–48, 50–57, 60, 62–64). The pooled analysis revealed substantial heterogeneity among the studies. Consequently, a random-effects model was applied for the analysis.

The pooled estimates for MMSE scores, reflecting cognitive status, were analyzed across three comparison patterns. In the 17 studies evaluating KTBAT combined with WMT, the random-effects meta-analysis showed no significant heterogeneity (I2 = 0%, p < 0.00001). KTBAT combined with WMT achieved a markedly higher improvement in MMSE scores (MD = 3.71, 95% CI: [2.96, 4.47], p < 0.00001). Similarly, when KTBAT monotherapy was compared to WMT (13 studies), a significant therapeutic advantage was observed (MD = 3.59, 95% CI: [2.60, 4.58], I2 = 87%, p < 0.00001). The two placebo-controlled crossover trials (35, 48) were not included in the quantitative synthesis (Figure 4).

Overall, the method of KTBAT, when used as an adjunctive therapy in combination with WMT, has the highest intensity in enhancing cognitive function and the most extensive evidence base.

To explore the sources of heterogeneity, subgroup analyses were performed according to dosage forms and treatment durations. In the combination therapy group, capsules (MD = 3.92, 95% CI: [3.13, 4.70]) and decoctions (MD = 3.87, 95% CI: [2.44, 5.30]) emerged as more effective forms, whereas granules showed no statistical difference (p = 0.29) (Supplementary Figure 1). For treatment duration, therapeutic effects were consistent from 1- to 6-month range, with the most pronounced MD observed at 1 month (MD = 5.88, 95% CI: [4.49, 7.26]), though 6 months interventions provided more robust evidence for long-term efficacy (MD = 3.72, 95% CI: [2.09, 5.34]) (Supplementary Figure 2). In the KTBAT monotherapy group, tablets and capsules were associated with greater improvement than mixtures, and the 6-month treatment subgroup showed the largest MMSE gain (MD = 4.85, 95% CI: [2.52, 7.19]) (Supplementary Figures 3, 4).

3.4.3HDS

Ten trials (28, 32, 34, 35, 38, 41, 43, 45, 48, 58) reported HDS scores as an outcome measure. After excluding the two crossover trials (35, 48), eight trials encompassing 837 patients were included in the quantitative synthesis. In the adjuvant therapy analysis, three studies evaluating KTBAT combined with WMT showed improved HDS scores (MD = 4.07, 95% CI: [2.63, 5.52], p < 0.00001). However, moderate heterogeneity was observed (I2 = 75%). After excluding (32) in a sensitivity analysis, heterogeneity was no longer detected (I2 = 0%), and the pooled result remained significant (MD = 4.76, 95% CI: [4.00, 5.52], p < 0.00001) (Supplementary Figure 5). In five studies evaluating KTBAT monotherapy, HDS scores also improved significantly (MD = 3.94, 95% CI: [0.83, 7.05], p = 0.01). However, substantial heterogeneity was observed (I2 = 98%), possibly due to clinical variation across studies (Figure 5). Overall, KTBAT combined with WMT provided the most consistent evidence among the three comparison patterns.

Subgroup analyses were conducted in the KTBAT monotherapy group according to dosage form and treatment duration. Tablets and herbal decoctions were associated with significant improvements in HDS scores (p < 0.00001), and the mixture subgroup also showed a favorable effect. By contrast, the capsule subgroup (2 studies) showed substantial heterogeneity (I2 = 99%) and did not reach statistical significance (p = 0.25) (Supplementary Figure 6).

For treatment duration, the 2-month subgroup (2 studies) showed a stable and significant benefit (MD = 3.81, 95% CI: [2.49, 5.14]) with no heterogeneity (I2 = 0%, p < 0.00001). The 3-month subgroup (2 studies) showed substantial heterogeneity (I2 = 99%) and was not statistically significant (p = 0.09). The 6-month protocol maintained a significant benefit compared with WMT (p = 0.008) (Supplementary Figure 7).

3.4.4CDR

Three trials assessed CDR scores (29, 36, 39). In the comparison of KTBAT combined with WMT, one study was included. The results indicated that KTBAT as an adjuvant therapy was associated with lower CDR scores than WMT alone (SMD = −0.87, 95% CI: [−1.26, −0.47], p < 0.0001). For KTBAT monotherapy versus WMT, two studies involving 272 participants were analyzed. The fixed-effect model analysis revealed no statistical heterogeneity (I2 = 0%, p = 0.89). KTBAT monotherapy was also more effective than WMT in improving clinical dementia ratings (SMD = −1.13, 95% CI: [−1.39, −0.88], p < 0.00001) (Figure 6).

3.4.5BDNF

This section included six studies (33, 38, 46–48, 60). After excluding the crossover trial (48), five studies encompassing 437 patients were included in the quantitative synthesis. These analyses examined serum neurotrophic factor levels as potential mechanistic markers. In the three studies evaluating KTBAT combined with WMT, the pooled estimate suggested that KTBAT may be associated with higher BDNF levels (SMD = 1.02, 95% CI: [0.13, 1.90], p = 0.02) although heterogeneity was substantial (I2 = 91%). After excluding (47) in the sensitivity analysis, the heterogeneity was eliminated and the pooled effect remained significant (SMD = 0.55, 95% CI: [0.23, 0.86], p = 0.0006, I2 = 0%) (Supplementary Figure 8). In the monotherapy analysis of 2 studies with 173 participants, the pooled result failed to reach statistical significance (SMD = 1.20, 95% CI: [−0.08, 2.48], p = 0.07). (Figure 7).

3.4.6NGF

Five RCTs reported NGF levels (29, 32, 40, 50, 60). These studies, involving 469 participants, were stratified into three subgroups according to measurement units (Figure 8). In the μg/L subgroup, which included two studies, KTBAT combined with WMT was associated with significantly higher NGF levels (SMD = 1.01, 95% CI: [0.51, 1.50], p < 0.0001). The ng/L subgroup, based on one study, showed a similar result (SMD = 1.03, 95% CI: [0.63, 1.44], p < 0.00001). However, the ng/mL subgroup which integrated two studies failed to show a statistically significant difference (SMD = 0.23, 95% CI: [−0.04, 0.51], p = 0.10). When all studies were pooled, the overall estimate still favored KTBAT combined with WMT (SMD = 0.69, 95% CI: [0.27, 1.12], p = 0.001).

3.4.7GDNF

Only one study reported the GDNF indicator (pg/mL) (29). This single trial involved 108 participants and compared KTBAT plus WMT with WMT monotherapy. The results showed that GDNF concentrations were significantly higher in the intervention group (MD = 56.56, 95% CI [44.84, 68.28], p < 0.00001) (Figure 9).

3.5Adverse events

Among the 38 included studies, 9 trials (23.7%) reported AEs (28, 32, 35, 38, 48–50, 60, 63). However, three crossover trials reported only combined-period or non-poolable AE data and were not included in the quantitative AE synthesis. Thus, 6 trials (15.7%) were included in the pooled AE analysis, 8 trials (21.1%) explicitly stated that no AEs occurred, 3 trials (7.8%) reported AEs but were not pooled, and the remaining 21 trials (55.3%) did not mention AEs. None of the original studies discontinued treatment due to AEs. In the six trials reporting AEs, a total of 48 participants experienced AEs (22 in the KTBAT groups and 26 in the control groups). No serious AEs or deaths were reported. The reported AEs included insomnia, diarrhea, abdominal pain, dizziness, and rash. A summary of AEs reported in each trial is presented in Table 2.

Table 2Adverse events of the included studies.

Included study N at risk (T/C) AEs in treatment group (specific manifestations, n) AEs in control group (specific manifestations, n) Any AE, n (%) (T/C) Discontinuation due to AE (T/C) AE reporting status

Guo et al. (28) 60/60 Rash (n = 2) Rash (n = 2), elevated AST (n = 3) 2 (3.3%) / 5 (8.3%) 0/0 Reported (with AEs)

Huang (32) 53/50 Mild blood pressure drop (n = 4), nausea and vomiting (n = 2), decreased appetite (n = 1) Dizziness (n = 2), mild blood pressure drop (n = 3), nausea (n = 1) 7 (13.2%) / 6 (12.0%) 0/0 Reported (with AEs)

Li (38) 119/119 Nausea, decreased appetite (n = 2) Dizziness (n = 2), gastrointestinal discomfort (n = 6) 2 (1.7%) / 8 (6.7%) 0/0 Reported (with AEs)

Wang et al. (50) 31/31 Mild frequent urination (n = 2), lower abdominal pain (n = 1), rash (n = 2) Mild frequent urination (n = 2), dizziness and nausea (n = 3), rash (n = 1) 5 (16.1%) / 6 (19.3%) 0/0 Reported (with AEs)

Yuan et al. (90) 50/50 Insomnia (n = 1), nausea and vomiting (n = 1), diarrhea (n = 2) Explicitly stated no AEs 4 (8%) / 0 0/0 Reported (with AEs)

Zhong et al. (63) 35/35 Diarrhea (n = 1), nausea (n = 1) Dizziness (n = 1) 2 (5.7%) / 1 (2.8%) 0/0 Reported (with AEs)

Jin et al. (35) 72/72 Dry mouth and sore throat (n = 2) Not pooled Not pooled Not pooled

Wang et al. (48) 18/18 Dry mouth and sore throat (n = 2) Not pooled Not pooled Not pooled

Wang et al. (49) 36/36 Dry mouth and sore throat (n = 4) Not pooled Not pooled Not pooled

Dou and Gao (27) 47/47 NR NR NR 0/0 Not mentioned

Han et al. (29) 54/54 NR NR NR 0/0 Not mentioned

Hu et al. (30) 50/50 NR NR NR 0/0 Not mentioned

Hu and Yu (31) 37/30 NR NR NR 0/0 Not mentioned

Jiang and Xu (33) 34/32 NR NR NR 0/0 Not mentioned

Jiang (34) 30/30 NR NR NR 0/0 Not mentioned

Li (36) 48/48 0 0 0 0/0 Explicitly stated no AEs

Li et al. (37) 57/53 0 0 0 0/0 Explicitly stated no AEs

Liu (39) 88/88 NR NR NR 0/0 Not mentioned

Lu et al. (40) 48/48 NR NR NR 0/0 Not mentioned

Ma et al. (41) 46/46 NR NR NR 0/0 Not mentioned

Man et al. (42) 47/47 0 0 0 0/0 Explicitly stated no AEs

Peng and Dong (43) 28/28 0 0 0 0/0 Explicitly stated no AEs

Shao (44) 31/24 NR NR NR 0/0 Not mentioned

Sheng et al. (45) 45/45 0 0 0 0/0 Explicitly stated no AEs

Tang et al. (46) 40/40 0 0 0 0/0 Explicitly stated no AEs

Tao et al. (47) 46/46 NR NR NR 0/0 Not mentioned

Wang (51) 30/30 0 0 0 0/0 Explicitly stated no AEs

Wang (52) 38/38 NR NR NR 0/0 Not mentioned

Wu et al. (53) 32/32 NR NR NR 0/0 Not mentioned

Wu (54) 50/50 NR NR NR 0/0 Not mentioned

Yang et al. (55) 38/37 0 0 0 0/0 Explicitly stated no AEs

Yang et al. (56) 42/40 NR NR NR 0/0 Not mentioned

Yao (57) 51/51 NR NR NR 0/0 Not mentioned

Yao and Yang (58) 39/39 NR NR NR 0/0 Not mentioned

Yu (59) 44/44 NR NR NR 0/0 Not mentioned

Zhao (61) 49/49 NR NR NR 0/0 Not mentioned

Zheng et al. (62)) 27/26 NR NR NR 0/0 Not mentioned

Zhu (64) 65/65 NR NR NR 0/0 Not mentioned

AST, aspartate aminotransferase; BP, blood pressure; C, control group; GI, gastrointestinal; NR, not reported; T, treatment group.

N at risk refers to the safety analysis population (participants who were randomized and received at least one dose of the allocated intervention). For trials reporting dropouts or exclusions before treatment initiation, N at risk = randomized number − number not receiving treatment. Percentages are calculated using N at risk as the denominator. “Reported (with AEs)” indicates that the trial provided adverse event data. “Explicitly stated no AEs” indicates that the trial actively stated that no AEs occurred (marked as 0). “Not mentioned” indicates that the trial did not mention AEs at all; this does not indicate the absence of AEs. “NR” indicates not reported. Enter “0” only when the original trial explicitly reports no AEs or no discontinuations due to AEs. Trials with dropouts should also be recorded as 0 if they clearly state that the dropouts were not due to AEs (e.g., participants were excluded before treatment at their own request). For crossover trials, only first-period data were eligible for pooling; combined-period or per-period repeated-measures data were not pooled. A total of 6 of 38 trials (15.7%) reported AEs, 8 trials (21.1%) explicitly stated no AEs, 3 trials (7.8%) did not pooled AEs and 21 trials (55.3%) did not mention AEs. No serious AEs or treatment-related deaths were reported in any included trial. All outcome measures related to the original study were complete, and none of the participants discontinued treatment due to AEs.

Three clinical trials reported safety outcomes for KTBAT plus WMT compared with WMT. No significant difference in AEs was observed between the two groups (I2 = 21%, RR = 0.85, 95% CI: [0.43, 1.68], p = 0.64). KTBAT monotherapy also showed comparable AEs rates to WMT (RR = 0.71, 95% CI: [0.32, 1.57], p = 0.40). (Figure 10). Sensitivity analyses, performed by removing each study in turn, did not materially change the results.

3.6Sensitivity analysis and publication bias

To evaluate the robustness of the pooled estimates, leave-one-out sensitivity analyses were performed for the primary outcomes. For the clinical effectiveness rate, both the KTBAT plus WMT group (22 studies) and the KTBAT monotherapy group (13 studies) showed consistent results, with no notable change in the pooled RRs after omitting any individual study. These results suggest that the findings for clinical efficacy were stable. However, funnel plots inspection revealed asymmetry in both groups, indicating a possible publication bias in the reporting of clinical effectiveness rate. Sensitivity analyses for MMSE scores were conducted in the KTBAT plus WMT group (17 studies) and the KTBAT monotherapy group (13 studies). Although the initial pooled analyses showed moderate-to-high heterogeneity, the leave-one-out analyses yielded stable results, and no single study had a substantial influence on the pooled MD. The funnel plots for MMSE scores in both groups were also asymmetrical (Figure 11), suggesting a potential small-study effect or selective reporting. Overall, despite the potential publication bias, the main findings on the effects of KTBAT on VaD remained robust across sensitivity analyses.

4Discussion

4.1Primary efficacy and safety outcomes

This systematic review analyzed 38 RCTs involving 3,357 participants to evaluate the efficacy and safety of KTBAT for VaD. To our knowledge, this is the first comprehensive meta-analysis to assess KTBAT for VaD. Our findings suggest that KTBAT, particularly when combined with WMT, was associated with improved clinical effectiveness and cognitive performance. In the combination therapy subgroup, MMSE and HDS scores showed greater improvements than WMT monotherapy. Although heterogeneity was observed in some cognitive outcomes, the overall direction of effect across the included studies was consistent, which supports the potential clinical value of KTBAT in different practice settings. However, it should be emphasized that these outcomes reflect symptomatic and cognitive improvement over a short treatment period, and they do not demonstrate that KTBAT modifies the underlying disease course of VaD. Importantly, statistically significant changes in serum biomarkers do not establish clinical benefit. Biomarkers are intermediate measures and are not surrogate endpoints for cognitive improvement or disease modification.

The observed clinical benefits of KTBAT may be partly explained by its multi-target and multi-level therapeutic effects. Pooled analyses suggested that KTBAT may be associated with higher serum BDNF, NGF, and GDNF levels. These neurotrophic factors are closely related to neuronal survival and synaptic plasticity. The observed changes may reflect a possible modulation of neurotrophic support, but the short-term nature of the included trials and the small number of studies mean that these findings do not establish that KTBAT attenuates neurological deficit or modifies the disease course.

Regarding safety, our results indicate that KTBAT does not significantly increase AEs compared with WMT. However, only six trials were included in the quantitative AE synthesis; three crossover trials reported AEs but were not pooled. The placebo-controlled evidence was limited and not quantitatively synthesised; therefore, the safety profile of KTBAT remains uncertain. In addition, the findings from the monotherapy analysis showed that KTBAT had comparable efficacy to conventional cognitive enhancers. This indicates that KTBAT may serve as an alternative therapeutic option for patients who cannot tolerate standard WMT.

4.2Subgroup findings and heterogeneity sources

Substantial heterogeneity was observed in the improvement of cognitive scales, particularly MMSE and HDS. To explore potential sources of this variability, we conducted stratified analyses based on dosage forms and treatment duration. The subgroup analysis of MMSE suggested that dosage forms may have influenced the observed clinical outcomes. In the combination therapy subgroup, capsules and decoctions were consistently associated with greater improvements than WMT, whereas granules did not show statistically significant differences. This pattern may be partly related to differences in the bioavailability of active components among formulations. It also suggests that traditional decoctions and modern capsules may provide more stable exposure of neuroprotective compounds.

Regarding treatment duration, cognitive improvements were generally observed across interventions lasting from 2 to 6 months. Notably, the 6-month subgroup provided the most consistent evidence of benefit in both monotherapy and combination therapy. This may indicate that KTBAT has a relatively sustained effect on cognitive outcomes in patients with VaD. By contrast, the 1-month subgroup showed larger mean differences in some trials, which may reflect early treatment effects or differences in study characteristics. However, other clinical factors did not fully account for the remaining heterogeneity. Differences in baseline dementia severity and individualized herb dosages may have contributed to the residual variance.

Methodological differences may provide another explanation for the heterogeneity. Variations in assessor training and in the administration of cognitive scales could have introduced measurement bias across study centers. Similarly, heterogeneity in BDNF and NGF assay sensitivity and reporting units may have affected the comparability of biomarker results. The lack of standardized herbal processing methods may also have led to differences in active ingredient content. In addition, the absence of stratification by VaD subtype, such as subcortical ischemic vascular dementia and multi-infarct dementia (65), during patient enrollment may also have contributed to the observed heterogeneity. Unfortunately, the limited reporting of these details prevented further meta-regression analyses. Nevertheless, the overall direction of effect sizes remained consistent across most subgroups, which supports the potential therapeutic value of KTBAT. Future studies should adopt more standardized protocols to reduce clinical and methodological heterogeneity.

4.3Pathophysiology of VaD and current treatments

VaD is a neurodegenerative disease that results from various cerebrovascular pathologies. Its pathogenesis involves multiple mechanisms, including apoptosis, inflammatory responses, and oxidative stress (66, 67). In addition, stroke, hypertension-related cerebral small vessel disease, and chronic cerebral hypoperfusion (CCH) are regarded as major contributors to cognitive decline in patients with VaD (68, 69). CCH can induce mitochondrial dysfunction and promote excessive reactive oxygen species (ROS) generation, thereby worsening blood–brain barrier (BBB) disruption, neuroinflammatory responses, and neuronal apoptosis, which may ultimately contribute to cognitive deterioration (70).

Currently, no drugs have been approved by the Food and Drug Administration (FDA) specifically for the treatment of VaD (5). As a result, medications approved for AD are often used in clinical practice to alleviate vascular cognitive impairment (71). Donepezil, galantamine, and memantine have been used in multiple regions to improve cognitive function in patients with VaD (72, 73). In light of the complex pathophysiology of VaD, the multi-target and multi-pathway strategies of TCM may offer potential for managing symptoms and cognitive impairment; however, disease-modifying effects remain unproven (74, 75). Diverse components derived from CHMs could ameliorate the neurovascular glial unit dysfunction in VaD (76, 77).

Additionally, some of the included trials used traditional Chinese medicine syndrome scores to assess clinical efficacy, suggesting that traditional Chinese medicine may help alleviate the accompanying symptoms of VaD, such as soreness in the lower back and knees and weakness. From a mechanistic perspective, BDNF is a key regulator of synaptic plasticity. Therefore, the relevant statistical findings in this study regarding KTBAT and neurotrophic factors may indicate that its mechanism of action is associated with synaptic remodeling and neuronal protection. It should be considered a hypothesis for future mechanistic research rather than evidence of disease modification.

4.4TCM theoretical framework for VaD

According to the theory of TCM, the brain is regarded as the “sea of marrow” (Nao Wei Sui Hai), whose functional state is intrinsically linked to the abundance of kidney essence (Shen Jing). Ancient TCM literature also describes “post-stroke amnesia” (Zhong Feng Hou Shan Wang), highlighting the recognized connection between cerebrovascular events and cognitive impairment. Within this theoretical framework, the etiology and pathogenesis of VaD are primarily attributed to kidney deficiency. Specifically, the proper functioning of the brain collaterals (Nao Luo) depends on nourishment from kidney essence; deficiency of this essence leads to an insufficient “sea of marrow,” resulting in inadequate nourishment of the brain. Additionally, Qi deficiency can impair the propulsion of blood, leading to blood stasis, which further obstructs the brain collaterals and exacerbates neurological damage. Kidney deficiency and blood stasis are also considered to be mutually reinforcing and can exacerbate each other in a vicious cycle. Therefore, “kidney deficiency and blood stasis” is considered an important pathological mechanism of VaD. Accordingly, the therapeutic principle of tonifying kidney essence and activating blood circulation to resolve stasis constitutes a common treatment approach for this condition. This principle is embodied in numerous classic herbal formulas, such as Dihuang Yinzi, Bushen Huoxue Tang, and Yisui Zengzhi Decoction.

4.5Pharmacological mechanisms of key CHMs

Based on the herbs most frequently used in KTBAT (Supplementary Table 2), we reviewed and summarized the relevant preclinical studies, briefly outlining their TCM effects and pharmacological mechanisms in relation to VaD.

Among the blood-activating herbs, Chuanxiong Rhizoma (76, 78, 79), Salviae Miltiorrhizae Radix et Rhizoma (80, 81), and Carthami Flos (82) may act primarily by improving hemodynamics, inhibiting thrombosis, and preserving endothelial integrity. In contrast, Paeoniae Radix Rubra (83, 84) predominantly contributes to the restoration of mitochondrial function, alongside the suppression of neuroinflammation and oxidative stress. Furthermore, Angelicae Sinensis Radix exhibits neuroprotective properties via cholinesterase inhibition (85, 86), which could potentially influence the clinical progression of AD and VaD (87, 88). In clinical practice, these herbs are often combined in paired formulations, such as Chuanxiong Rhizoma coupled with Angelicae Sinensis Radix, as well as Salviae Miltiorrhizae Radix et Rhizoma paired with Carthami Flos, in order to enhance their blood-activating effects.

Regarding kidney-tonifying ingredients, Polygoni Multiflori Radix Praeparata (89), Polygonati Rhizoma (90), and Schisandrae Chinensis Fructus (91, 92), may exert pharmacological effects mainly by reducing oxidative damage, attenuating neuronal apoptosis, and modulating microglia-mediated inflammatory responses. Similarly functioning as a classical botanical pair, Cistanches Herba (93, 94) and Epimedii Herba (95, 96) demonstrate a combined capacity to inhibit cellular apoptosis, modulate neurotransmitter levels for cholinergic neuroprotection, and subsequently ameliorate blood–brain barrier dysfunction. Additionally, Cornel iridoid glycoside (CIG) has been reported to modulate neurotrophic factor expression within the cortex and hippocampus of rats subjected to chronic cerebral ischemia (97), while simultaneously downregulating microglia-driven inflammation (98).

Collectively, the therapeutic effects of KTBAT in VaD are unlikely to depend on a single pathway. Instead, they may reflect a coordinated biological response involving both improved cerebral perfusion through blood-activating herbs and enhanced neuronal resilience through kidney-tonifying herbs. However, these mechanistic interpretations are largely based on preclinical evidence and indirect clinical markers. Clinically, these mechanisms may inspire future multi-target research, but they require confirmation in long-term, adequately powered trials.

5Limitations

This review has several limitations. First, the overall methodological quality of the included RCTs was relatively low, as the majority of studies lacked detailed descriptions of blinding procedures, rendering them susceptible to performance and detection biases. Second, because all of the included studies were conducted in China, the generalizability of the findings to other populations may be limited. Third, the included studies predominantly consisted of single-center trials with small sample sizes, which may limit statistical power. Fourth, long-term follow-up data were generally lacking across these trials, precluding a definitive assessment of the therapy’s long-term efficacy and safety. Neurotrophic factor outcomes were reported in only a small subset of trials, and the available short-term data do not establish disease-modifying effects. Fifth, three crossover trials could not be included in the quantitative synthesis because only combined-period or non-poolable data were reported; this may have limited the assessment of safety and placebo-controlled effects. Additionally, although comprehensive subgroup analyses were performed for outcomes with substantial heterogeneity, some residual heterogeneity remained unexplained. Finally, the variations in herbal formulations and concurrent WMT regimens complicated the interpretation of the true treatment effect.

6Conclusion

This study provides modern evidence-based support for the TCM theory of “kidney deficiency and blood stasis” in VaD. Current evidence suggests that KTBAT, as an adjunct therapy or monotherapy, may improve clinical effectiveness and cognitive function in patients with VaD; however, its safety profile is not well established due to limited AE reporting. Given the suboptimal methodological quality and inherent heterogeneity of the included studies, these findings warrant further confirmation through large-scale, high-quality RCTs. Future clinical investigations should prioritize multi-center, randomized, double-blind, placebo-controlled designs with standardized outcome measures and extended follow-up durations. Moreover, we recommend incorporating TCM syndrome scales to precisely stratify specific populations with the “Kidney Deficiency and Blood Stasis” syndrome, thereby optimizing syndrome-prescription correspondence. Concurrently, advanced technologies such as network pharmacology and molecular biology could be used to further elucidate the underlying pharmacological mechanisms and critical target pathways of KTBAT in combating dementia.

References

1.Iadecola C Duering M Hachinski V Joutel A Pendlebury ST Schneider JA . Vascular cognitive impairment and dementia: JACC scientific expert panel . J Am Coll Cardiol . (2019 ) 73 :3326 –44 . doi: 10.1016/j.jacc.2019.04.034 , 31248555 PMC6719789

2.Cai Y Mok VCT Markus HS . Vascular dementia: world stroke organization fact sheet 2026 . Int J Stroke . (2026 ) 21 :152 –63 . doi: 10.1177/17474930251404243 , 41479247 PMC12831815

3.Jia L Du Y Chu L Zhang Z Li F Lyu D . Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study . Lancet Public Health . (2020 ) 5 :e661 –71 . doi: 10.1016/s2468-2667(20)30185-7 , 33271079

4.Wolters FJ Ikram MA . Epidemiology of vascular dementia . Arterioscler Thromb Vasc Biol . (2019 ) 39 :1542 –9 . doi: 10.1161/atvbaha.119.311908 , 31294622

5.Lennon MJ Sachdev PS . Vascular cognitive impairment and dementia: prevention, treatments, mechanisms and management options for the future . Neuropsychopharmacology . (2026 ). doi: 10.1038/s41386-026-02331-3 , 41554956

6.Livingston G Huntley J Liu KY Costafreda SG Selbæk G Alladi S . Dementia prevention, intervention, and care: 2024 report of the lancet standing commission . Lancet . (2024 ) 404 :572 –628 . doi: 10.1016/s0140-6736(24)01296-0 , 39096926

7.Peng Y. Jin H. Xue Y.H. Chen Q. Yao S.Y. Du M.Q. (2023 ). Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks . Front Aging Neurosci
15 :1206572 . doi: 10.3389/fnagi.2023.1206572 , 37600514.PMC10438465 37600514

8.Zuliani G Brombo G Romagnoli T Polastri M Dario FDP Zuin M . Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia . Geroscience . (2026 ) 48 :7191 –202 . doi: 10.1007/s11357-025-02052-3 , 41396413 PMC13601481

9.Dong W Tian Z Bai J Wu B Zhao M Zhang Y . Polygenic risk score and cluster-based analysis suggests links between type 2 diabetes and vascular dementia in the KARE study . Nat Commun . (2025 ) 16 :10135 . doi: 10.1038/s41467-025-65252-7 , 41258170 PMC12630647

10.Dang C Wang Q Zhuang Y Li Q Feng L Xiong Y . Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis . Front Pharmacol . (2024 ) 15 :1451032 . doi: 10.3389/fphar.2024.1451032 , 39239652 PMC11374729

11.McShane R Westby MJ Roberts E Minakaran N Schneider L Farrimond LE . Memantine for dementia . Cochrane Database Syst Rev . (2019 ) 3 :Cd003154 . doi: 10.1002/14651858.CD003154.pub6 , 30891742 PMC6425228

12.Sun R Chen C Fu Z He L Fan H Xu L . Qizhi Tongluo capsule improves vascular dementia in rats via integrated metabolomics and molecular mechanism research . J Ethnopharmacol . (2026 ) 356 :120787 . doi: 10.1016/j.jep.2025.120787 , 41167571

13.Lee JY Han K Kim J Lim JS Cheon DY Lee M . Association between metabolic syndrome and young-onset dementia: a Nationwide population-based study . Neurology . (2025 ) 104 :e213599 . doi: 10.1212/wnl.0000000000213599 , 40267374

14.Deng X Teng J Nong X Yu B Tang L Liang J . Characteristics of TCM constitution and related biomarkers for mild cognitive impairment . Neuropsychiatr Dis Treat . (2021 ) 17 :1115 –24 . doi: 10.2147/ndt.S290692 , 33907404 PMC8068505

15.Wang Q Zhang L Xu R Meng K Pan L Zhang X . Metabolic syndrome and risk of dementia and cognitive decline: a systematic review and meta-analysis of prospective cohort studies from 6,753,197 participants . Geroscience . (2025 ). doi: 10.1007/s11357-025-02014-9 , 41252085

16.Liu D Zhao Y Liu R Qiao B Lu X Bei Y . Traditional Chinese medicine as a viable option for managing vascular cognitive impairment: a ray of hope . Medicine (Baltimore) . (2025 ) 104 :e41694 . doi: 10.1097/md.0000000000041694 , 40101029 PMC11922442

17.Hu R Yin CL Wu N Cui GY Meng H Wu XG . Traditional Chinese herb Dihuang Yinzi (DY) plays neuroprotective and anti-dementia role in rats of ischemic brain injury . J Ethnopharmacol . (2009 ) 121 :444 –50 . doi: 10.1016/j.jep.2008.09.035 , 19000752

18.Kim DW Kim SH Kook HJ Jung IC . Efficacy and safety of Buyang-Huanwu-Tang (Boyang-Hwano-Tang) in patients with vascular dementia: a systematic review and meta-analysis . Complement Ther Clin Pract . (2022 ) 47 :101547 . doi: 10.1016/j.ctcp.2022.101547 , 35168040

19.Ye S. Gu Y. Xu Y. Fan W. Wang X. Chen S. (2014 ). Bushen huoxue decoction improves cognitive decline in rats with cerebral hypoperfusion . Mol Med Rep
10 , 1635 –1641 . doi: 10.3892/mmr.2014.2355 , 24968700.24968700

20.Chan ES Bautista DT Zhu Y You Y Long JT Li W . Traditional Chinese herbal medicine for vascular dementia . Cochrane Database Syst Rev . (2018 ) 2018 :Cd010284 . doi: 10.1002/14651858.CD010284.pub2 , 30520514 PMC6516869

21.Li B Wang J Wang B Wang X Zhu G Yang S . Therapeutic potential of genus Polygonatum in common neuropsychiatric disorders: the revival of an ancient remedy in modern medicine . J Ethnopharmacol . (2025a ) 350 :120052 . doi: 10.1016/j.jep.2025.120052 , 40441463

22.Wu S Huang R Zhang R Xiao C Wang L Luo M . Gastrodin and Gastrodigenin improve energy metabolism disorders and mitochondrial dysfunction to antagonize vascular dementia . Molecules . (2023 ) 28 :2598 . doi: 10.3390/molecules28062598 , 36985572 PMC10059574

23.Zhao Z Xie L Shi J Liu T Wang S Huang J . Neuroprotective effect of Zishen Huoxue decoction treatment on vascular dementia by activating PINK1/parkin mediated mitophagy in the hippocampal CA1 region . J Ethnopharmacol . (2024 ) 319 :117172 . doi: 10.1016/j.jep.2023.117172 , 37709106

24.Ningning Y Ying X Xiang L Yue S Zhongda W Ruoyu J . Danggui-Shaoyao San alleviates cognitive impairment via enhancing HIF-1α/EPO axis in vascular dementia rats . J Ethnopharmacol . (2024 ) 331 :118306 . doi: 10.1016/j.jep.2024.118306 , 38723920

25.Zheng SG Ye RL Huang XN Ye WJ Li H Zeng NX . From medicinal herb to neuroprotective candidate: a review of curculigoside's potential in central nervous system disorders . J Ethnopharmacol . (2026 ) 359 :121048 . doi: 10.1016/j.jep.2025.121048 , 41419043

26.Sun X Xie Y Fang R Zeng S Lin S Tang X . Real-world efficacy and safety of Zishenyizhi pill for cognitive impairment associated with cerebral small vessel disease: protocol for a Multicenter prospective observational study . JMIR Res Protoc . (2025 ) 14 :e77661 . doi: 10.2196/77661 , 41217122 PMC12723357

27.Dou F Gao Y . Clinical observation of Naoxintong capsules combined with piracetam tablets for vascular dementia of blood stasis obstructing collaterals type . Guizhou Med J . (2023 ) 47 :707 –8 . doi: 10.3969/j.issn.1000-744X.2023.05.017 , (in Chinese)

28.Guo T Lei L Cheng PR Chen YB . Treatment for 60 cases of vascular dementia by kidney-invigorating blood-activating tablets . West J Tradit Chin Med . (2019 ) 32 :75 –7 . doi: 10.3969/j.issn.1004-6852.2019.06.024 , (in Chinese)

29.Han SS Dong Y Liu XX . Effect of modified Yisui Zengzhi decoction on cognitive function, serum BDNF and ET levels for patients with vascular dementia of kidney-deficiency blood-stasis syndrome . J Sichuan Tradit Chin Med . (2021 ) 39 :165 –8 . doi: 10.3969/j.issn.1000-3649.2021.12.sczy202112050 , (in Chinese)

30.Hu CC Qin HW Ji LS Zhao PL . Clinical study of Dihuangyinzi in the treatment of vascular dementia of kidney deficiency and blood stasis type . Chin J Convalescent Med . (2023 ) 32 :306 –9 . doi: 10.13517/j.cnki.ccm.2023.03.019 , (in Chinese)

31.Hu YN Yu X . Treatment of 67 cases of vascular dementia with Fuyuan decoction . Shaanxi J Tradit Chin Med . (2013 ) 9 :40 –1 . doi: 10.3969/j.issn.1000-7369.2013.09.019 , (in Chinese)

32.Huang GM . Effects of Naoxintong capsules on cerebral blood flow, neurotrophy, and nerve injury in patients with vascular dementia . Chin J Integr Med Cardio-Cerebrovasc Dis . (2021 ) 19 :1040 –3 . doi: 10.12102/j.issn.1672-1349.2021.06.038 , (in Chinese)

33.Jiang Y Xu F . Clinical observation of Aricept combined with Naoxintong capsule in treatment of vascular dementia after cerebral infarction . Med J West China . (2014 ) 26 :698 –700 . doi: 10.3969/j.issn.1672-3511.2014.06.008 , (in Chinese)

34.Jiang YY . Treatment of 30 cases of vascular dementia with Buchang Naoxintong . Fujian J Tradit Chin Med . (2006 ) 5 :7 –9 . doi: 10.13260/j.cnki.jfjtcm.009026 , (in Chinese)

35.Jin XM Li L Lian LX Song ZH . Clinical investigation of Jiannao Yizhi capsule to improving vascular dementia sufferer on nerve function damage . Chin Arch Tradit Chin Med . (2007 ) 25 :1657 –9 . doi: 10.3969/j.issn.1673-7717.2007.08.051 , (in Chinese)

36.Li SC . Efficacy evaluation of self-prepared Bushen Huoxue Yizhi decoction in the auxiliary treatment of elderly patients with vascular dementia . J Huaihai Med . (2021 ) 39 :299 –301 . doi: 10.14126/j.cnki.1008-7044.2021.03.028 , (in Chinese)

37.Li SG Dai SW Li QW . Dihuang Yinzi capsule combined with Denepezil in treatment of vascular dementia . Zhejiang J Integr Tradit Chin West Med . (2015 ) 25 :632 –634+643 . doi: 10.3969/j.issn.1005-4561.2015.07.006 , (in Chinese)

38.Li YH . Levels of Livin, VEGF, IL-18 and IFN-γ in vascular dementia patients treated with Naoxintong capsule: clinical observation of 238 . Inf Tradit Chin Med . (2017 ) 34 :67 –70 . doi: 10.3969/j.issn.1002-2406.2017.04.019 , (in Chinese)

39.Liu YQ . Observation on effect of butylphthalide combined with Bushen Yizhi decoction in treatment of senile vascular dementia . Clin Med . (2018 ) 38 :110 –3 . doi: 10.19528/j.issn.1003-3548.2018.06.047 , (in Chinese)

40.Lu LB Li W Zhang Y Fang L Zhu Y Li X . Effect of Naoxintong capsule on cognitive function improvement and vascular endothelial glycocalyx indexes in patients with vascular dementia . Chin J Gerontol . (2022 ) 42 :625 –8 . doi: 10.3969/j.issn.1005-9202.2022.03.034 , (in Chinese)

41.Ma XM Lian XL He J Chen Z Huang H Chen QY . Study on the effect of Bushen Huoxue decoction combined with donepezil hydrochloride on cognitive function and hemorheology in vascular dementia . Chin J Mod Appl Pharm . (2019 ) 36 :604 –8 . doi: 10.13748/j.cnki.issn1007-7693.2019.05.019 , (in Chinese)

42.Man B Liu YY Wang Q Yuan Z . Clinical study on Naoxintong capsules combined with memantine hydrochloride in treatment of vascular dementia . Drugs Clin . (2019 ) 34 :979 –83 , (in Chinese)

43.Peng W Deng HL . Comparative study on clinical effects of activating blood to remove stasis and tonifying kidney to replenish essence in treating vascular dementia . J Changchun Univ Tradit Chin Med . (2007 ) 23 :29 –30 . doi: 10.3969/j.issn.1007-4813.2007.06.020 , (in Chinese)

44.Shao YZ . Clinical observation on Xingnaofusu decoction in treating senile vascular dementia . Hebei J Tradit Chin Med . (2003 ) 25 :253 –5 . doi: 10.3969/j.issn.1002-2619.2003.04.004 , (in Chinese)

45.Sheng CX Su NX He MD Pan SG . Clinical observation of Buchang Naoxintong capsule in the treatment of vascular dementia . Contemp Med . (2009 ) 15 :157 –8 . doi: 10.3969/j.issn.1009-4393.2009.27.128 , (in Chinese)

46.Tang XJ Lao YR Yang ZM Huang PX Luo XD . Clinical study on modified Bushen Huoxue decoction in treating vascular dementia . J Guangzhou Univ Tradit Chin Med . (2005 ) 6 :8 –11 . doi: 10.13359/j.cnki.gzxbtcm.2005.06.002 , (in Chinese)

47.Tao YL Cao M Chen X . Clinical study on Yizhi decoction combined with oxiracetam in treating vascular dementia of kidney deficiency and blood stasis type . Henan Tradit Chin Med . (2017 ) 37 :446 –8 . doi: 10.16367/j.issn.1003-5028.2017.03.0157 , (in Chinese)

48.Wang FW Jiang N Tong ZQ Wang ZK Tian JH Liu Y . Clinical study of Shenlong decoction in improving neurological deficits in patients with vascular dementia . Chin J Clin Rehabil . (2004 ) 4 :679 –81 . doi: 10.3321/j.issn:1673-8225.2004.04.068 , (in Chinese)

49.Wang FW Wang ZK Jiang N Hao AZ Tong ZQ Tian JH . Clinical study on the effect of Shenlong decoction on vascular dementia . J Chin PLA Postgrad Med Sch . (2005 ) 2 :93 –5 . doi: 10.3969/j.issn.1005-1139.2005.02.005 , (in Chinese)

50.Wang LG Kou SJ Su HJ Zheng CH Wu Q . Effects of Bushen Huazhuo Huoxue decoction combined with memantine hydrochloride on cerebral hemodynamics and cognitive function in patients with vascular dementia . Henan Med Res . (2024 ) 33 :743 –6 . doi: 10.3969/j.issn.1004-437X.2024.04.040 , (in Chinese)

51.Wang SF . Treatment of 30 cases of vascular dementia with Xinjia Dihuang Yinzi . J Shaanxi Coll Tradit Chin Med . (2015 ) 38 :36 –7 . doi: 10.13424/j.cnki.jsctcm.2015.05.014 , (in Chinese)

52.Wang TS . Clinical study on modified Tongqiao Huoxue decoction combined with oxiracetam in treating vascular dementia of blood stasis obstructing orifices type . Mod J Integr Tradit Chin West Med . (2016 ) 25 :316 –317+342 . doi: 10.3969/j.issn.1008-8849.2016.03.035 , (in Chinese)

53.Wu LC Liu HF Ji LS . Clinical observation of modified Dihuang Yinzi combined with donepezil hydrochloride tablets in the treatment of vascular dementia . Chin J Drug Abuse Prev Treat . (2025 ) 31 :1324 –6 . doi: 10.15900/j.cnki.zylf1995.2025.07.045 , (in Chinese)

54.Wu QF . Analysis of 50 cases of vascular dementia treated from theory of toxin damaging the brain collateral . New J Tradit Chin Med . (2021 ) 53 :32 –5 . doi: 10.13457/j.cnki.jncm.2021.02.008 , (in Chinese)

55.Yang HW Yang JJ Hao ZQ Chen LL Shen YF Wei PF . Study on the mechanism of Jiawei Dihuang decoction in treating vascular dementia and the exploration on susceptibility genes based on whole exome sequencing technology . Chin J Inf Tradit Chin Med . (2025 ) 32 :134 –41 . doi: 10.19879/j.cnki.1005-5304.202502357 , (in Chinese)

56.Yang P You FH Lin JJ . Evaluation of combination therapy and prognosis of vascular dementia . Electron J Clin Med Lit . (2019 ) 6 :46 . doi: 10.16281/j.cnki.jocml.2019.23.032 , (in Chinese)

57.Yao H . Clinical research on combination of traditional Chinese and Western medicine treatment of vascular dementia in elderly patients with syndrome of kidney deficiency and phlegm turbidity . J Chin Med . (2017 ) 32 :1008 –1010, 1014 . doi: 10.16368/j.issn.1674-8999.2017.06.264 , (in Chinese)

58.Yao YJ Yang PF . Effect of Naoxintong capsule combined with nimodipine on vascular dementia . Henan Med Res . (2021 ) 30 :3211 –3 . doi: 10.3969/j.issn.1004-437X.2021.17.046 , (in Chinese)

59.Yu Y . Clinical effect observation of Wenshen Huoxue formula in treating vascular dementia of kidney yang deficiency and blood stasis syndrome . Chin J Clin Ration Drug Use . (2018 ) 11 :25 –6 . doi: 10.15887/j.cnki.13-1389/r.2018.05.013 , (in Chinese)

60.Yuan QQ Zhang Q . Clinical research on the treatment of vascular dementia with kidney deficiency and blood stasis syndrome by combining modified Bushen Huayu formula with conventional western medicine . Chin J Convales Med . (2025 ) 34 :49 –53 . doi: 10.13517/j.cnki.ccm.2025.11.010 , (in Chinese)

61.Zhao HY . Effect of Tongqihuoxue decoction combined with bufophthalein softgel on daily living ability and symptom score of patients with vascular dementia . Diet Health Care . (2024 ) 10 :93 –6 . (in Chinese)

62.Zheng DJ Xu J Fang SX Pan JY Fang JZ . Effect of Buchang Naoxintong on behavioral disorders in patients with vascular dementia . Inf Tradit Chin Med . (2009 ) 26 :75 –6 . doi: 10.19656/j.cnki.1002-2406.2009.04.044 , (in Chinese)

63.Zhong BH Xue WX Chen W . Clinical efficacy of Bushenhuoxue decoction in treatment of vascular dementia and its effect on serum Livin and BDNF levels . Hubei J Tradit Chin Med . (2020 ) 42 :3 –5 .Available online at: https://kns.cnki.net/kcms2/article/abstract?v=xiNUFhx2xxYrmWjYvGKqadtPmA04WRGDKdKvvAbfNEcBXUnwhszNTgHZ7hbOcaEavFEXoQ3ZOWJ638mMrjc0fajkTZb3nKXxlZbLNG_w-brgOvK8md78uFUk6Hf3RmlU0Ztjm8FYsjLf1CJGyHYAz1TszeeXC0137_1w_yCUrYjCzSRVnKyXZA==
(in Chinese)

64.Zhu YJ . Clinical observation of nimodipine combined with Naoxintong in the treatment of 65 cases of vascular dementia . Jilin Med J . (2015 ) 36 :3871 –2 . doi: 10.3969/j.issn.1004-0412.2015.17.081 , (in Chinese)

65.Inoue Y Shue F Bu G Kanekiyo T . Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease . Mol Neurodegener . (2023 ) 18 :46 . doi: 10.1186/s13024-023-00640-5 , 37434208 PMC10334598

66.Sarhan M Wohlfeld C Perry-Mills A Meyers J Fadel J Murphy EA . The pathophysiology of mixed Alzheimer's disease and vascular dementia . Theranostics . (2025 ) 15 :9793 –818 . doi: 10.7150/thno.118737 , 41041058 PMC12486426

67.Venkat P Chopp M Chen J . Models and mechanisms of vascular dementia . Exp Neurol . (2015 ) 272 :97 –108 . doi: 10.1016/j.expneurol.2015.05.006 , 25987538 PMC4631710

68.Hainsworth AH Markus HS Schneider JA . Cerebral small vessel disease, hypertension, and vascular contributions to cognitive impairment and dementia . Hypertension . (2024 ) 81 :75 –86 . doi: 10.1161/hypertensionaha.123.19943 , 38044814 PMC10734789

69.Markus HS Joutel A . The pathogenesis of cerebral small vessel disease and vascular cognitive impairment . Physiol Rev . (2025 ) 105 :1075 –171 . doi: 10.1152/physrev.00028.2024 , 39965059 PMC12182829

70.Lv H Liu Y Yang X Xu X Zhou J Yu W . Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment . J Stroke Cerebrovasc Dis . (2025 ) 34 :108475 . doi: 10.1016/j.jstrokecerebrovasdis.2025.108475 , 41110565

71.Craig D Birks J . Rivastigmine for vascular cognitive impairment . Cochrane Database Syst Rev . (2005 ) 2 :Cd004744 . doi: 10.1002/14651858.CD004744.pub2 15846730

72.Battle CE Abdul-Rahim AH Shenkin SD Hewitt J Quinn TJ . Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis . Cochrane Database Syst Rev . (2021 ) 2 :Cd013306 . doi: 10.1002/14651858.CD013306.pub2 PMC8407366 33704781

73.Goodall LS Lennon MJ Sachdev PS Gorelick PB Kovacic JC Samaras K . Current and emerging therapeutic approaches for vascular cognitive impairment and dementia . J Am Coll Cardiol . (2026 ) 87 :77 –100 . doi: 10.1016/j.jacc.2025.09.1502 , 41498480

74.Wang D Yao H Wang L Lu B Liu W Li J . Gut-brain axis and vascular dementia: a review on mechanisms and Chinese herbal medicine therapeutics . Front Microbiol . (2025a ) 16 :1564928 . doi: 10.3389/fmicb.2025.1564928 , 40438206 PMC12116591

75.Zhao T Pan P Jia Y Zhou Y Zhang X Guan H . Crossing pathological boundaries: multi-target restoration of the neurovascular unit in Alzheimer's and vascular dementia-from modern therapeutics to traditional Chinese medicine . Aging Dis . (2025 ) 2353 –81 . doi: 10.14336/ad.2025.0801 PMC13437122 40901978

76.Chen L Zhen Y Wang X Wang J Zhu G . Neurovascular glial unit: a target of phytotherapy for cognitive impairments . Phytomedicine . (2023 ) 119 :155009 . doi: 10.1016/j.phymed.2023.155009 , 37573807

77.Zhao D Yi Y He Q Wang S Yang K Ge J . Exploring the regulatory mechanism of Nao tai Fang on vascular dementia's biological network based on cheminformatics and transcriptomics strategy . J Ethnopharmacol . (2021 ) 274 :114065 . doi: 10.1016/j.jep.2021.114065 , 33771644

78.Lim S Lim C Cho S . Methanol extract of Ligusticum chuanxiong Hort. Rhizome ameliorates bilateral common carotid artery stenosis-induced cognitive deficit in mice by altering microglia and astrocyte activation . Front Pharmacol . (2024 ) 15 :1329895 . doi: 10.3389/fphar.2024.1329895 , 38549667 PMC10973115

79.Ma KT Wu YJ Yang YX Wu T Chen C Peng F . A novel phthalein component ameliorates neuroinflammation and cognitive dysfunction by suppressing the CXCL12/CXCR4 axis in rats with vascular dementia . J Ethnopharmacol . (2024 ) 328 :118117 . doi: 10.1016/j.jep.2024.118117 , 38548120

80.Chan K Chui SH Wong DY Ha WY Chan CL Wong RN . Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction . Life Sci . (2004 ) 75 :3157 –71 . doi: 10.1016/j.lfs.2004.06.010 , 15488895

81.Shi CG Yang YS Li H Zhang Y Wang N Wang SM . Tanshinol protects hippocampus and attenuates vascular dementia development . J Asian Nat Prod Res . (2014 ) 16 :667 –76 . doi: 10.1080/10286020.2014.930131 , 24957473

82.Zhang P He S Wu S Li Y Wang H Yan C . Discovering a multi-component combination against vascular dementia from Danshen-Honghua herbal pair by Spectrum-effect relationship analysis . Pharmaceuticals (Basel) . (2022 ) 15 :1073 . doi: 10.3390/ph15091073 , 36145294 PMC9505896

83.Hong H Lu X Wu C Chen J Chen C Zhang J . A review for the pharmacological effects of paeoniflorin in the nervous system . Front Pharmacol . (2022 ) 13 :898955 . doi: 10.3389/fphar.2022.898955 , 36046834 PMC9420976

84.Liu J Wang JS Kong LY . Comparative pharmacokinetics of paeoniflorin in plasma of vascular dementia and normal rats orally administrated with Danggui-Shaoyao-San or pure paeoniflorin . Fitoterapia . (2011 ) 82 :466 –73 . doi: 10.1016/j.fitote.2010.12.004 , 21185921

85.Liao X Zhang Z Ming M Zhong S Chen J Huang Y . Imperatorin exerts antioxidant effects in vascular dementia via the Nrf2 signaling pathway . Sci Rep . (2023 ) 13 :5595 . doi: 10.1038/s41598-022-21298-x , 37019901 PMC10076271

86.Nogami-Hara A Nagao M Takasaki K Egashira N Fujikawa R Kubota K . The Japanese Angelica acutiloba root and yokukansan increase hippocampal acetylcholine level, prevent apoptosis and improve memory in a rat model of repeated cerebral ischemia . J Ethnopharmacol . (2018 ) 214 :190 –6 . doi: 10.1016/j.jep.2017.12.025 , 29269276

87.Kim M Song M Oh HJ Hui J Bae W Shin J . Evaluating the memory enhancing effects of Angelica gigas in mouse models of mild cognitive impairments . Nutrients . (2019 ) 12 :97 . doi: 10.3390/nu12010097 , 31905851 PMC7019643

88.Peng D Qiao HZ Tan HY Wang YX Luo D Qiao LJ . Ligustilide ameliorates cognitive impairment via AMPK/SIRT1 pathway in vascular dementia rat . Metab Brain Dis . (2022 ) 37 :1401 –14 . doi: 10.1007/s11011-022-00947-0 , 35420377

89.Wu F Li Y Liu W Xiao R Yao B Gao M . Comparative investigation of raw and processed Radix Polygoni Multiflori on the treatment of vascular dementia by liquid chromatograph-mass spectrometry based metabolomic approach . Meta . (2022 ) 12 :1297 . doi: 10.3390/metabo12121297 , 36557335 PMC9785642

90.Yuan Y Li M Zhou T Chen X Li Y . Polygonati Rhizoma alleviates vascular dementia through regulating microglial polarization transitions mediated by NF-κB/NLRP3 pathway . Curr Pharm Biotechnol . (2026 ) 27 :444 –61 . doi: 10.2174/0113892010336948241209172018 , 39936434

91.He JB Zhang H Zheng HX Jia JX Zhang YC Yan XS . Effects of schisandrin B on hypoxia-related cognitive function and protein expression in vascular dementia rats . J Toxicol Environ Health A . (2024 ) 87 :421 –7 . doi: 10.1080/15287394.2024.2334247 , 38551405

92.Li S Gao Y Zhang X Lang J Liu X Zhang Y . Bicyclol improves cognition deficits and inhibits oxidative stress-induced neuronal cell apoptosis in alzheimer's disease via Nrf2/HO-1 pathway . Metab Brain Dis . (2025b ) 40 :310 . doi: 10.1007/s11011-025-01738-z , 41196440

93.Yang H Hao Z Miao F . Research progress of pharmacological mechanism of Cistanche in the treatment of vascular dementia . J Contemp Med Pract . (2024 ) 6 :17 –21 . doi: 10.53469/jcmp.2024.06(09).04

94.Zhang YM Wu W Ma W Wang F Yuan J . Effect of glycosides of Cistanche on the expression of mitochondrial precursor protein and keratin type II cytoskeletal 6A in a rat model of vascular dementia . Neural Regen Res . (2017 ) 12 :1152 –8 . doi: 10.4103/1673-5374.211196 , 28852399 PMC5558496

95.Xie C Tang H Liu G Li C . Molecular mechanism of Epimedium in the treatment of vascular dementia based on network pharmacology and molecular docking . Front Aging Neurosci . (2022 ) 14 :940166 . doi: 10.3389/fnagi.2022.940166 , 36051307 PMC9424771

96.Yuan P Chen W Wang X Li L Peng Z Mu S . RAGE: a potential target for epimedium's anti-neuroinflammation role in vascular dementia-insights from network pharmacology and molecular simulation . J Biomol Struct Dyn . (2024 ) 42 :10856 –75 . doi: 10.1080/07391102.2023.2259480 , 37732621

97.Wang MY Meng M Yang CC Zhang L Li YL Zhang L . Cornel iridoid glycoside improves cognitive impairment induced by chronic cerebral hypoperfusion via activating PI3K/Akt/GSK-3β/CREB pathway in rats . Behav Brain Res . (2020 ) 379 :112319 . doi: 10.1016/j.bbr.2019.112319 , 31669346

98.Zheng C Yang C Gao D Zhang L Li Y Li L . Cornel iridoid glycoside alleviates microglia-mediated inflammatory response via the NLRP3/calpain pathway . J Agric Food Chem . (2022 ) 70 :11967 –80 . doi: 10.1021/acs.jafc.2c03851 , 36104266

Come citare questo studio

Mengdie Zhou, Mengqi Che, Chao Zhang, Xiaoyu Yang, Xile Liu, Zhihao Liu, Ju Huang, Hua He. (2026). Efficacy and safety of traditional Chinese medicine kidney-tonifying and blood-activating therapy in the treatment of vascular dementia: a systematic review and meta-analysis.. Frontiers in neurology. DOI: 10.3389/fneur.2026.1901245

Consulta la pubblicazione originale ↗